Market Overview

UPDATE: Morgan Stanley Reiterates On Mindray Medical International Ltd. On In-Line 1Q14 Sales Growth

Related MR
Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio
Will Mindray Medical Go Private And List In China?

In a report published Tuesday, Morgan Stanley analyst Bin Li reiterated an Equal-Weight rating on Mindray Medical International Ltd. (NYSE: MR), but removed the $37.00 price target.

In the report, Morgan Stanley noted, “MR reported in-line 1Q14 sales growth on continued weak China business but stabilized ex-China growth, while non-GAAP profit was also in line. Notably, operating income was 13% below our estimate, but helped by the lower tax rate. Given the challenging China environment and the departure of the COO, Mr. Liu Jie, who has been instrumental to Mindray's healthy growth in the past few years, we do not expect improving profit growth in the near term.”

Mindray Medical International Ltd. closed on Monday at $33.67.

Latest Ratings for MR

Jun 2015JMP SecuritiesUpgradesUnderperformMarket Perform
Mar 2015Credit SuisseDowngradesNeutralUnderperform
Mar 2015JMP SecuritiesMaintainsMarket Underperform

View More Analyst Ratings for MR
View the Latest Analyst Ratings

Posted-In: Bin Li Morgan StanleyAnalyst Color Price Target Analyst Ratings


Related Articles (MR)

Get Benzinga's Newsletters